Last reviewed · How we verify

Menopur®, Ferring

Instituto Valenciano de Infertilidad, IVI VALENCIA · FDA-approved active Small molecule

Menopur is a purified preparation of human menopausal gonadotropins (hMG) containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and hormone production.

Menopur is a purified preparation of human menopausal gonadotropins (hMG) containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and hormone production. Used for Controlled ovarian hyperstimulation in assisted reproductive technology (ART) cycles, Ovulation induction in anovulatory women.

At a glance

Generic nameMenopur®, Ferring
SponsorInstituto Valenciano de Infertilidad, IVI VALENCIA
Drug classGonadotropin
TargetFSH receptor (FSHR) and LH receptor (LHCGR)
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhaseFDA-approved

Mechanism of action

Menopur contains equal amounts of FSH and LH extracted from the urine of postmenopausal women. FSH directly stimulates follicle growth and estrogen production in the ovaries, while LH supports follicle maturation and triggers ovulation. This combination mimics the natural hormonal environment needed for controlled ovarian stimulation in assisted reproductive procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results